Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (151-160 of 179) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
Cancer Cell|May 13, 2020
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in CancerJian Carrot-Zhang, Nyasha Chambwe, Jeffrey S Damrauer, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
Cancers|November 13, 2025
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible PatientsMorteza Salehjahromi, Hui Li, Eman Showkatian, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Cancer Cell|March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
JCO Precision Oncology|April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic ToxicityMitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Pageof 18

Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
Cancer Cell|May 13, 2020
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in CancerJian Carrot-Zhang, Nyasha Chambwe, Jeffrey S Damrauer, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
Cancers|November 13, 2025
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible PatientsMorteza Salehjahromi, Hui Li, Eman Showkatian, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Cancer Cell|March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
JCO Precision Oncology|April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic ToxicityMitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
Pageof 18